Systemic Sclerosis Associated Interstitial Lung Disease clinical trials

Explore recruiting systemic sclerosis associated interstitial lung disease clinical trials.

Recruiting systemic sclerosis associated interstitial lung disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Systemic Sclerosis Associated Interstitial Lung Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2/3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (SSc-ILD)

Germany, Greece, France, Finland, Denmark, Spain +2 more

Phase II and Phase III (Integrated) EU CTIS Study details

Exploratory, non-randomized, 3-group, microdosing clinical trial to investigate Gallium-68 (68Ga) labeled Platelet-Derived Growth Factor Beta (PDGFRß) targeting Positron Emission Tomography (PET) tracer (68Ga-ATH001) binding in the lungs in healthy participants versus participants with Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

Sweden

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Germany, Hungary, Italy, France, Poland, Belgium +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Systemic Sclerosis Associated Interstitial Lung Disease trials by city

Systemic Sclerosis Associated Interstitial Lung Disease in Toronto Systemic Sclerosis Associated Interstitial Lung Disease in Vancouver Systemic Sclerosis Associated Interstitial Lung Disease in Montreal Systemic Sclerosis Associated Interstitial Lung Disease in Calgary Systemic Sclerosis Associated Interstitial Lung Disease in Edmonton Systemic Sclerosis Associated Interstitial Lung Disease in Ottawa Systemic Sclerosis Associated Interstitial Lung Disease in Winnipeg Systemic Sclerosis Associated Interstitial Lung Disease in Quebec City Systemic Sclerosis Associated Interstitial Lung Disease in Hamilton Systemic Sclerosis Associated Interstitial Lung Disease in Kitchener Systemic Sclerosis Associated Interstitial Lung Disease in London Systemic Sclerosis Associated Interstitial Lung Disease in Halifax Systemic Sclerosis Associated Interstitial Lung Disease in New York Systemic Sclerosis Associated Interstitial Lung Disease in Los Angeles Systemic Sclerosis Associated Interstitial Lung Disease in Chicago Systemic Sclerosis Associated Interstitial Lung Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease